Yong Fan

Yong Fan

Auto-generated profile, based on publicly available information

Yong Fan

The Second Hospital of Lanzhou University, Lanzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Medicine
Verified
Journal Article
Open access
XCXiaxia Chen
Xiaxia Chen
QWQiuya Wei
Qiuya Wei
RJRuirui Jing
Ruirui Jing
YFYong Fan
Yong Fan
Background: Digestive tumor is one of the most common cancers, its symptoms and treatment will bring patients with anxiety, depression and other negative emotions, and cause cancer-related fatigue. As a new complementary replacement therapy, music therapy can greatly reduce cancer-related fatigue, anxiety and depression, and achieve good clinical results, but there is a lack of evidence-based medicine. The purpose of this study is to evaluate the effect of music therapy on cancer-related fatigue, anxiety, and depression in patients with digestive tumors by meta-analysis. Method: Computer search of Chinese and English databases: Wanfang, VP Information Chinese Journal Service Platform, China National Knowledge Infrastructure, Chinese BioMedicine Literature Database and pubmed, embase, cochrane, web of science. A comprehensive collection of relevant studies on the effects of music therapy on digestive tract cancer-related fatigue, anxiety and depression, the retrieval time is from the date of establishment to March 2021. According to the inclusion and exclusion criteria, the literature is selected, the quality of the literature is evaluated and the data are extracted. The data are analyzed by meta-analysis. Result: The purpose of this study is to evaluate the effect of music therapy on digestive tract cancer-related fatigue, anxiety, and depression by European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire, Hamilton Depression Scale, and Hamilton Anxiety Scale . Conclusion: This study will provide reliable evidence-based evidence for the clinical application of music therapy in the treatment of digestive tract cancer-related fatigue and anxiety and depression. OSF Registration number: DOI 10.17605/OSF.IO/UR4GV.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
FMFulin Ma
Fulin Ma
YFYong Fan
Yong Fan
LZLina Zhang
Lina Zhang
ZZZhiqiang Zhao
Zhiqiang Zhao
YNYuanhua Nie
Yuanhua Nie
CWChen Wang
Chen Wang
Objective. To evaluate Roux‐en‐Y and Billroth II reconstruction following pancreaticoduodenectomy (PD). Methods. PubMed, Embase, the Cochrane Library, and the Web of Science were searched to identify randomized controlled trials (RCTs) and controlled clinical trials that compared Roux‐en‐Y and Billroth II reconstruction following PD up to December 2019. RevMan 5.3 software was used for the statistical analysis. Results. Four RCTs and five controlled clinical trials were included, with a total of 1,072 patients (500 and 572 patients in the Roux‐en‐Y and Billroth II groups, respectively). No significant differences in delayed gastric emptying (DGE), A‐grade DGE, B‐grade DGE, or C‐grade DGE were observed between the Roux‐en‐Y and Billroth II reconstruction groups after PD (odds ratio [OR] = 1.01, 95% confidence interval [CI]: 0.50–2.03, P = 0.98; OR = 0.49, 95% CI: 0.17–1.45, P = 0.20; OR = 0.63, 95% CI: 0.29–1.38, P = 0.25; and OR = 2.13, 95% CI: 0.38–11.99, P = 0.39). No significant difference in the incidence of postoperative pancreatic fistula, abscess, bile leaks, infection, postoperative bleeding, or the length of the postoperative hospital stay was observed between the Roux‐en‐Y and Billroth II groups (P > 0.05), but the operation time was significantly different (mean difference [MD] = 31.65, 95% CI: 7.14–56.17, P = 0.01). Conclusions. Billroth II reconstruction after PD did not significantly reduce the incidence of DGE or other complications but shortened the operation time compared to Roux‐en‐Y reconstruction. However, the results must be verified by further high‐quality, large RCTs or controlled clinical trials.

3 November 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
HGHaobo Gou
Haobo Gou
LZLing Zhong
Ling Zhong
QWQiuya Wei
Qiuya Wei
YFYong Fan
Yong Fan
Introduction: Animal and clinical studies have demonstrated a range of potential health benefits associated with cinnamon. However, its effects on metabolic parameters such as blood glucose, blood pressure, lipid profiles, and body weight in patients with metabolic diseases remain controversial. To systematically assess the current evidence, we conducted an umbrella review of meta-analyses to comprehensively evaluate the impact of cinnamon supplementation on metabolic outcomes in patients with metabolic diseases. Methods: A systematic search was performed in PubMed, Embase, Web of Science, Scopus, and the Cochrane Library to identify relevant systematic reviews and meta-analyses of randomized placebo-controlled trials investigating cinnamon supplementation in individuals with metabolic diseases. The methodological quality and strength of evidence were assessed using AMSTAR 2 tool (A MeaSurement Tool to Assess systematic Reviews, version 2). Results: A total of 21 meta-analyses comprising 139 comparisons, were included for qualitative synthesis. The findings indicate that cinnamon supplementation is significantly associated with improvements in fasting blood glucose and lipid profiles, with more pronounced effects observed in patients with diabetes and metabolic syndrome. Subgroup analyses suggest that higher doses (>1.5 g/day) and shorter intervention durations (≤2 months) may enhance these benefits. Additionally, cinnamon shows potential in modulating insulin resistance, antioxidant capacity, and blood pressure regulation. Conclusion: These results underscore the promising role of cinnamon as an adjunctive therapy for metabolic diseases. Future research should focus on well-designed randomized controlled trials with extended follow-up periods to further confirm its efficacy and elucidate underlying mechanisms, thereby providing robust evidence for clinical and public health applications. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251010073 , identifier: CRD420251010073.

17 April 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
JCJie Chen
Jie Chen
KHKeshu Hu
Keshu Hu
JLJun Lu
Jun Lu
HPHongda Pan
Hongda Pan
YHYakai Huang
Yakai Huang
FLFenglin Liu
Fenglin Liu
Neoadjuvant therapy (NAT) is a cornerstone in the treatment of locally advanced gastric cancer, improving surgical outcomes and survival. However, the optimal timing for surgery following NAT remains controversial. This study evaluates the impact of the interval between NAT and surgery on overall survival (OS) and explores associated clinicopathological factors. A retrospective analysis of 893 patients undergoing NAT and curative surgery for gastric adenocarcinoma across three centers in China was conducted. Surgical intervals were categorized (∼28 days, 29-42 days, >42 days). Survival analyses employed restricted cubic spline (RCS) models, Kaplan-Meier methods, and Cox proportional hazards regression. Patients operated on within 28 days post-NAT had the most favorable OS, while intervals longer than 28 days were independently associated with worse outcomes. RCS analysis revealed increased risks for intervals longer than 28 days. Prolonged intervals showed declining effectiveness in tumor regression. Stratified analyses indicated that patients with poor NAT response (TRG 3) particularly benefited from surgery within 4 weeks, while delays were detrimental. Timely surgery, especially within 4 weeks post-NAT, optimizes survival outcomes, particularly in patients with limited NAT response. This study underscores the need for individualized surgical timing and calls for prospective multicenter validation.

12 September 2025 in Luminescence
Verified
Journal Article
Closed access
JFJie Fu
Jie Fu
YFYong Fan
Yong Fan
YLYongyong Liu
Yongyong Liu
BKBoxiong Kang
Boxiong Kang
QWQiuya Wei
Qiuya Wei
MTMuzhou Teng
Muzhou Teng